Novavax, Inc. (NVAX)
9.70
-0.29
(-2.90%)
USD |
NASDAQ |
Oct 23, 16:00
9.70
0.00 (0.00%)
After-Hours: 20:00
Novavax Enterprise Value : 1.177B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.177B |
| October 22, 2026 | 1.224B |
| October 21, 2026 | 1.393B |
| October 20, 2026 | 1.462B |
| October 19, 2026 | 1.361B |
| October 16, 2026 | 1.434B |
| October 15, 2026 | 1.691B |
| October 14, 2026 | 1.661B |
| October 13, 2026 | 1.691B |
| October 12, 2026 | 1.665B |
| October 09, 2026 | 1.679B |
| October 08, 2026 | 1.393B |
| October 07, 2026 | 1.427B |
| October 06, 2026 | 1.444B |
| October 05, 2026 | 1.648B |
| October 02, 2026 | 1.302B |
| October 01, 2026 | 1.325B |
| September 30, 2026 | 1.360B |
| September 29, 2026 | 1.361B |
| September 28, 2026 | 1.358B |
| September 25, 2026 | 1.330B |
| September 24, 2026 | 1.325B |
| September 23, 2026 | 1.317B |
| September 22, 2026 | 1.363B |
| September 21, 2026 | 1.294B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.244B |
| September 17, 2026 | 1.226B |
| September 16, 2026 | 1.119B |
| September 15, 2026 | 1.099B |
| September 14, 2026 | 1.159B |
| September 11, 2026 | 1.131B |
| September 10, 2026 | 1.111B |
| September 09, 2026 | 1.201B |
| September 08, 2026 | 1.257B |
| September 04, 2026 | 1.262B |
| September 03, 2026 | 1.282B |
| September 02, 2026 | 1.279B |
| September 01, 2026 | 1.246B |
| August 31, 2026 | 1.122B |
| August 28, 2026 | 1.104B |
| August 27, 2026 | 1.070B |
| August 26, 2026 | 1.096B |
| August 25, 2026 | 1.134B |
| August 24, 2026 | 1.038B |
| August 21, 2026 | 1.051B |
| August 20, 2026 | 965.73M |
| August 19, 2026 | 1.027B |
| August 18, 2026 | 884.97M |
| August 17, 2026 | 908.04M |
| August 14, 2026 | 904.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 75.99B |
| Merck & Co., Inc. | 405.39B |
| Pfizer Inc. | 222.94B |
| Amgen, Inc. | 280.78B |
| Editas Medicine, Inc. | 228.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.39M |
| Revenue (Quarterly) | 56.70M |
| Total Expenses (Quarterly) | 110.08M |
| EPS Diluted (Quarterly) | -0.3244 |
| Gross Profit Margin (Quarterly) | 77.70% |
| Profit Margin (Quarterly) | -94.16% |
| Earnings Yield | -15.70% |
| Normalized Earnings Yield | -9.468 |